Physician profile
Marshall D Shoemaker
NPI 1659321065
$9,611.64
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,568 · 2020: $1,360 · 2021: $1,886 · 2022: $884 · 2023: $1,006 · 2024: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.73 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $2,126.39 | 2019-2023 | Saffron |
| Minerva Surgical, INC | $1,598.98 | 2019 | |
| Abbvie INC. | $698.60 | 2019-2024 | Ubrelvy |
| Pfizer INC. | $529.81 | 2019-2024 | |
| Astellas Pharma US INC | $486.09 | 2019-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $440.95 | 2022-2024 | |
| Therapeuticsmd, INC. | $436.27 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $339.41 | 2023-2024 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $263.20 | 2019-2024 | |
| Eisai INC. | $205.51 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $190.62 | 2019-2022 | |
| Novo Nordisk INC | $180.98 | 2019-2020 | |
| Allergan, INC. | $150.18 | 2019-2020 | |
| Urovant Sciences INC | $133.37 | 2021-2022 | |
| Boston Scientific Corporation | $121.24 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.